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Abstract. We have used compactin, an inhibitor of
mevalonate biosynthesis, to block p21- posttransla-
tional modification and membrane association in PC12
cells. Previous studies have demonstrated a require-
ment for isoprenylation for mitogenic effects of acti-
vated p2l- in mammalian cells and for function of
RAS gene products in yeast. Immunoprecipitation of
[3IS]methionine-labeled p21- from PC12 cell homoge-
nates confirmed that the processed p21- species is
missing from compactin-treated PC12 cells. Immuno-
precipitation from particulate and cytosolic fractions
of PC12 cells confirmed that compactin blocks p21-
membrane association: p2l- is confined to the cytosol
fraction . Induction of neuronal differentiation and orni-
thine decarboxylase (ODCase) transcription by onco-
genic p2IN-- does not occur in compactin-treated cells
indicating that activity of oncogenic p2 IN-- expressed
in PC12 cells is abolished by compactin treatment.
T
HE ras protooncogene proteins, p21"--, p21K--, and
p21N-=, are members of a family of small membrane-
associated GTP-binding proteins. Although the pre-
cise mechanism of action is unclear, p21- proteins appear
to be involved in signal transduction: coupling ofintercellu-
lar signals to cellular response mechanisms (4, 6, 32, 52 for
recent reviews). In particular, p2l- proteins appear to be
involved in transduction of mitogenic signaling. More recent
studies (5, 26, 49, 57, 58) have indicated that p21- proteins
may also play a role in the transductionofsignals that induce
cell differentiation, specifically, neuronal differentiation in-
duced by nerve growth factor (NGF)l in PC12 cells,
p21- proteins are associated with the cytoplasmic sur-
face of the plasma membrane (63). This association is due
to posttranslational modifications which involve covalent at-
tachment of lipid to the protein . Palmitic acid is attached to
Portions of this work have been presented in abstract form. Green, S. H.,
M.S. Qiu, andA. F . Pitts. 1990. Rasproto-oncogene metabolism and post-
translational modification in the PC12 neuronal cell line: relevance to ques-
tion of ras involvement in NGF signal transduction. J . Cell. Physiol. 14:
F94(Abstr.).
1. Abbreviations used in this paper: FGF, fibroblast growth factor; NGF,
nerve growth factor; ODCase, ornithine decarboxylase.
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Thus, p21- isoprenylation or association with the mem-
brane appears to be required for early responses and
neuronal differentiation attributable to p2l-, activation.
In contrast, blockade of p21- isoprenylation and mem-
brane association by compactin treatment did not sig-
nificantly reduce PC12 cell responses to NGE Re-
sponses examined included rapid phosphorylation of
tyrosine hydroxylase, rapid induction of ODCase ex-
pression, survival in serum-free medium and neuronal
differentiation . Compactin blocked growth factor-in-
duced rapid changes in cell surface morphology but
did so whether this response was induced by NGF or
by EGF. These results indicate that functional p2l- is
not necessary for responses to NGF which in turn im-
plies that if a ras-dependent NGF signal transduction
pathway exists, as has been previously suggested, at
least one additional ras-independent pathway must also
be present.
one or more cysteines near the COOH-terminus (9) of most
p21- proteins, although not p21K-- transcribed with exon
4B (33) . Since p21K-5(B) proteins are not palmitoylated yet
can associate with the membrane and transform cells (33),
palmitoylation is apparently not necessary for ras function.
However, all p2l- proteins are isoprenylated: isoprenoid,
probably a farnesyl moiety (11, 56), is covalently attached to
the COOH-terminal cysteine (33, 53) . The signal for iso-
prenylation is the COON-terminal 4-amino acid CAAX mo-
tif (C=cysteine, A=any aliphatic amino acid, X=any amino
acid), which all rasproteins possess. Otherproteins thatpos-
sess this COOH-terminal sequence, such as nuclear lamin
(64), G protein y subunit (18, 19), or Saccharomycescerevi-
siae mating hormone a-factor (2), are also isoprenylated.
Recombinant heterologous proteins to which the CAAX
COOH-terminal sequence has been added are also isopren-
ylated, indicating thatthismotifis sufficient, as well as neces-
sary, for isoprenylation (33). The isoprenoid used for protein
isoprenylation is derived from mevalonate as part of a meta-
bolic pathway that also gives rise to sterols, ubiquinone and
dolichol (7). Thus, drugs such as lovastatin (1, 17) or com-
pactin (17) which inhibit HMG-CoA (hydroxymethylglutaryl
coenzyme A) reductase and thus blockmevalonate synthesis
also inhibitprotein isoprenylation (42, 51). Isoprenylation of
795p21-, in particular, is blocked by these drugs (33, 45, 53)
and, in Saccharomyces cerevisiae, also by mutations which
abolish mevalonate synthesis (53) . Posttranslational modi-
fication ofp21- also involves two additional steps (13, 29):
(a) proteolytic removal of the COOH-terminal three amino
acids, AAX; (b) carboxyl methylation, inadditionto isopren-
ylation, of the cysteine now at the COOH-terminal. These
steps too appear to require isoprenylation (33, 35, 45, 53).
Isoprenylation of p21- appears to be necessary for its lo-
calization to the membrane. Inhibition of mevalonate syn-
thesis by mutation or drug treatment results in cytosolic lo-
calization of ras proteins in yeast and mammalian cells (33,
53) and mutations that eliminate the CAAX cysteine abolish
membrane localization of mammalian p21- (33, 35). Inhi-
bition of ras isoprenylation in S. cerevisiae results in loss of
ras biological activity (53). Transforming activity of onco-
genic mutant ras in mammalian cells and Xenopus oocytes,
is abolished in the absence of isoprenylation (35, 53). In
metazoan cells the functions of ras are not understood as
well as they are in yeast and the requirement for isoprenyla-
tion for normal ras biological activity, as opposed to trans-
forming activity of oncogenic p2l- has hitherto not been
investigated.
In PC12 cells, expression of oncogenic ras genes results,
not in transformation or mitogenic responses, but in neu-
ronal differentiation similar to that which occurs after treat-
ment with NGF or fibroblast growth factor (FGF) . Since in-
hibition of ras function can inhibit PC12 responses to NGF
and FGF (30, 49, 57), it has been suggested that ras proteins
may function in NGF signal transduction pathway. This sys-
tem allows experimental study of the function of ras in the
induction of differentiation, as opposed to induction of trans-
formation by oncogenic ras mutants. In the present study we
have used compactin treatment of PC12 cells to assess the
role of PC12 cells to assess the role of p21-s isoprenylation
and membrane localization in its differentiation-inducing ac-
tivity. We have also exploited this system to more closely ex-
amine the function of p21- in NGF signal transduction.
Our results indicate that.isoprenylation is required for neu-
ronal differentiation induced by a transforming mutant
p21N--s but not by NGF. This implies that the role of p21-s
in NGF signal transduction is not a necessary one, an idea
consistent with previous suggestions that NGF signal trans-
duction involves multiple parallel pathways.
Materials andMethods
Materials
Unless otherwise noted, reagents were obtained from VWRScientific Corp.
(Philadelphia, PA), Fisher Scientific (Fair Lawn, NJ) or Sigma Chemical
Co. (St. Louis, MO). Compactin was provided by Dr. Akira Endo and
lovastatin by Dr. Alfred Alberts. These HMG-CoA reductase inhibitors
were dissolved in ethanol which was alkalinized with an equal volume of
0.1 M NaOH. The drugs were dissolved by heating to 50°C for 2 h. They
were then neutralized with 0.1 M HCl and diluted to stock concentration
(1,000X working concentration) for storage.
Cell CultureandMicroscopy
PC12 cells and cells of the PC12-derived UR61J line (provided by David
Burstein) were maintained, as described in detail in Greene et al. (24), on
collagen-coated tissue culture dishes in 85% RPMI 1640 medium (Gibco
Laboratories, Grand Island, NY) + 5% FBS (Gibco Laboratories) + 10%
heat-inactivated donor horse serum (Hazelton Biologics, Inc., Herndon,
The Journal of Cell Biology, Volume 115, 1991
VA). NGF was prepared as described in Mobley et al . (48) Y13-259 hybrid-
oma cells (obtained from American Type Culture Collection, Rockville,
MD) were maintained in DMEM plus 10% FBS. All culture media were
supplementedwith 100 U/mlpenicillin plus 100pg/ml streptomycin (Gibco
Laboratories).
Cells were generally observed by phase-contrast microscopy. Phase con-
trastphotomicrographs were taken ofcells immediately after removal from
the 37°C/6.5`ío C02 incubator. Growth factor-induced cell surface move-
ments were observed using Hoffman optics and contrast-enhanced video
(Hamamatsu Corp., Hamamatsu City, Japan). For these experiments, be-
cause the cells had to be maintained for several minutes outside ofthe incu-
bator, the culture medium was replaced with iso-osmolar RPMI 1640 me-
dium containing 25 mM Hepes, pH 7.4 and the cells were kept on a
microscope stage heated to 37°C.
MetabolicRadiolabeling ofCells
Cellular proteins were labeled by adding 50-100 uCi/ml [35S]Met/Cys
(Tran35S-label; ICN Radiochemicals, Irvine, CA) directly to the culture
medium for 24 h (W cells in a 60-mm culture dish). Phosphoproteins
were labeled by incubating 2 x 106 cells in a 35-mm dish in 1 ml HBSG
(HEPES-buffered saline plus glucose = 137 mM NaCl, 2.7 mM KCI, 1.2
mM CaC12, 0.5 MM MgC12, 1 mg/ml glucose, 25 mM HEPES, pH 7.4)
plus 100 pCi [32P]Na3 (PO4) (ICN Radiochemícals) for 2 h at 37°C. The
incubation was terminated by removal ofthe culture medium and washing
with PBS (137 mM NaCl, 2.7 mM KCI, 1.2 mM CaC12, 0.5 MM MgC12,
9.6 mM sodium phosphate, pH 7.1). Cholesterol uptake was assessed by the
addition of 5 ACilml [3H]cholesterol to the culture medium, washing the
cellswith PBS, solubilizingthecells inPBS plus 1% Triton X-100 plus0.196
SDS, and assaying cell-associated radioactivity in a scintillation counter.
Immunoprecipitation ofp21-Proteins
Rabbit anti-rat conjugated protein A-Sepharose (RAR-PAS) was made by
adding 10 mg of BSA in 1 ml PBS to 100 mg protein A-Sepharose beads
(Pharmacia Fine Chemicals, Piscataway, NJ) and incubating overnight on
a rotator at 4°C in a microfuge tube. The beads were recovered by a 3-min
centrifugation at 13,000 g, washed four times with PBS and resuspended
in 1 ml PBS. 150 X of rabbit anti-rat IgG (Zymed Corp., San Francisco,
CA) at 1 mg/ml was addedandthe beadswere incubated overnight onarota-
tor at4°C. The beads were recoveredby a 3-mincentrifugation at 13,000 g,
washed five times with PBS and resuspended in 150 )` PBS plus 0.05%
NaN3.
Cells were solubilized in 400 X PBSTDS (150 mM NaCl, 0.5% sodium
deoxycholate, 1% Triton X-100, 0.1% SDS, 0.2% NaN3, 10 mM sodium
phosphate pH 7.3, 0.5 ;kg/ml leupeptin, 1 mM EDTA, 0.7 pg/mI pepstatin,
0.2 mM PMSF) and centrifuged at 13,000 g for 60 min at 4°C. RAR-PAS
(20 A) was added to the supernatant, the mixture was incubated overnight
on a rotator at 4°C in a microfuge tube, and centrifuged at 13,000 g for
3 min. The supernatant was transferred to a fresh tube, 40 X Y13-259 cul-
ture supernatant or control medium was added, and the mixture was incu-
bated on ice for 60 min. RAR-PAS (20 X) was added and the mixture was
incubated overnight onarotator at4°C. Thebeads were recovered by centri-
fugation at 13,000 g for 3 min and washed twice with PBSTDS, once with
PBSTDS plus 1 M NaCl, and three times with PBSTDS. Thewashed beads
were boiled for 5-10 min in SDS-PAGE SB (5% 2-mercaptoethanol, 2 %
SDS, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 62.5 mM Tris-Cl, pH6.8),
loaded onto 4-cm 17% polyacrylamide gels, and run according to Laemmli
(36). Fixed, Coomassie blue-stained gels were soaked for in 1 M sodium
salicylate/40% methanol, dried, and exposed to preflashed Kodak XAR-5
film (37). Autoradiograms were scanned on a Hoefer densitometer (Hoefer
Scientific Instruments, San Francisco, CA) for quantitation of radioactivity
in bands.
Preparation ofParticulate andCytosolic Fractions
All steps were performed on ice with ice-cold solutions unless otherwise
noted. Cells were washed twice with H2O, scraped up into 400 X lysis
buffer (5 MM M9Cl2, 0.5 pg/ml leupeptin, 0.7 pglml pepstatin, 0.2 mM
PMSF, 10 mM Hepes, pH 7.3) with a rubber policeman and transferred to
a prechilled Dounce homogenizer. After swelling for 15 min the cells were
disrupted with 15 strokes of the B pestle. Nuclei and unbroken cells were
removed by centrifugation in a microcentrifuge at 3,000rpm for 2 min. The
supernatant was transferred to a Beckman airfuge and centrifuged at
100,000 g for 20 min. For immunoprecipitation, an equal volume of 2x
PBSTDS was added tothe cytosolic fraction (supernatant) and the particu-
796Figure 1 . Compactin inhibits
posttranslational modification
ofp21-1 . PC12 or UR61J cells
were subjected to the indicated
experimental or control treat-
ments . During the final24 hof
the incubation [35S]Met was
added, the cells were solu-
bilized, and p21- immuno-
precipitated, as described in
Materials and Methods . Cell
homogenatescontainedapprox-
imately equal amounts of
TCA-precipitable radioactivity.
In this and other figures, auto-
radiograms were exposed for
equal times to show the rela
tive amount of p21- protein in the cells under all ofthe conditions
used . Positions of molecular weight standards are indicated adja-
cent to each autoradiogram . An arrow indicates the position of
p21- . (A) UR611 cells were labeled with [35S]Met for 24 h in the
presence (+) or absence (-) of 5 uM dexamethasone (DEX)
to show, respectively, endogenous p21^u or induced oncogenic
p21"' .In either case, the cells were incubated additionally in the
presence or absence of 3 /ug/ml compactin, as indicated, to show
effects of compactin on endogenous p21- and on induced onco-
genic p21'-- .Compactin, if present, was added to cell cultures
6 h before initiation of [35S]Met labeling to deplete cellular meva-
lonate pools. DEX, if present, was added at the same time as
[35S]Met . In all cases stock solutions of compactin andDEX were
added at a dilution ofat least 1,000x . (B)PC12 cells were cultured
for24 or 96hin the presence (+ ) or absence (-) of 3 Etglnil com-
pactin (COM) as indicated . The lane labeled "no Ab" is a control
immunoprecipitation performed in the same way as the other im-
munoprecipitations but with no Y13-259 antibody, demonstrat-
ing that no proteins are nonspecifically immunoprecipitated with
our protocol .
late fraction (pellet), which includes the membranes, was solubilized in
300 A PBSTDS .
RNA Preparation and Northern Blotting
Total RNA was prepared by the method of Chomczynski and Sacchi (12)
and fractionated on formaldehyde-agarose gels (10 lAgRNA/slot) essentially
as described by Ausubel et al . (3) but with 0.5 Etg/ml ethidium bromide
added to the RNA to allow subsequent visualization of the RNA and
verification of equal loadingamong samples . TheRNAwas transferred to
ZetaProbe (Bio-Rad Laboratories, Richmond, CA) in IOx SSC (150mM
NaCl, 1.5 mM sodium citrate, pH 7.0), UV-cross -linked, and prehybridized
in5x SSC,4x Denhardt's,50% formamide, 10% dextransulfate, 1% SDS,
12.5 kg/ml sonicated calf thymus DNA . cDNA probes were radiolabeled
using random primers (Bethesda Research Laboratories, Gaithersburg,
MD) according to the manufacturer's protocol and added to the prehybridi-
zation buffer for anovernight incubation at 42°C . Filters were briefly rinsed
in 2x SSC/0.2% SDSand then washed three times for 30 min each at 42°C
in O.lx SSC/0.1% SDS, exposed to preflashed XAR-5 film using an inten-
sifying screen (Dupont Corp ., Wilmington, DE) . Autoradiograms were
scanned on a Hoeferdensitometer for quantitation of radioactivity in bands .
Analysis ofPhosphoproteins
Growth factors, if present, were added to the culture dishes 1 h before
solubilizing the cells.
32plabeled cells were solubilized in 200 X SDS-
PAGE buffer addeddirectly to the 35 mm dish and scraped up with a rubber
policeman . Samples containing equal amounts ofTCA-precipitable radioac-
tivity were loaded on 20-cm 7.5-15% polyacrylamide gradient gels. Gels
were Coomassie blue-stained, fixed and dried, and exposed to preflashed
XAR-5 film using an intensifying screen . Autoradiograms were scanned on
a Hoefer densitometer for quantitation ofradioactivity in bands . Quantita-
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tion of optical density was corrected for differences among lanes in loading
or exposure by scanning two regions ofthe autoradiogram unaffected by ex-
perimental treatment and normalizing density ofthe bands of interest to this
background .
Results
Compactin Blocksp21- Pbsttranslational
Modification in UR61J Cells andPC12 Cells
The UR61J cell line, described in detail in Guerrero et al .
(27), is derived from the PC12 subline U7. U7 cells exhibit
some responsesto NGF, e.g ., enhanced proliferation (8) and
cfos induction (58), but, unlike PC12 cells, undergo NGF-
induced neuronal differentiation and neurite outgrowth only
under growth-arresting conditions (8) . UR61J cells share
these properties (27) . An oncogenic N-ras gene with a
MMTV (murine mammary tumor virus) promoter was sta-
bly introduced into U7 cells to generate the UR61J cell line
(27) . TheMMTV promoter is activated by glucocorticoids;
thus expression ofoncogenic N-ras is induced in UR6IJ cells
by addition of dexamethasone (DEX) to the culture medium,
resulting in neuronal differentiation . DEX does not induce
neuriteoutgrowth or cfostranscription in U7 cells nordoes
it inhibit these responses if induced by NGF (27, 58) . Fig .
1 A shows p21- immunoprecipitated from UR61J cells.
Comparison ofproteinimmunoprecipitated fromDEX-treated
cells with that from DEX-untreated cells shows a large in-
crease due to the addition of DEX-induced p21"-- to theen-
dogenous pool of p21-, . Data from Northern blot analysis
(27) confirm that the DEX-induced protein is p21 "- r°s .
Expression of mutant oncogenic p21- proteins in PC12
cells results in cessation of cell proliferation and neuronal
differentiation including neuriteoutgrowth (5, 26,49) . Thus,
induction ofoncogenic p21 N-- expression by DEX in UR61J
cells results in neuronal differentiation of this PC12-derived
line (27) . Among the rapid responses to oncogenic p21N-r°s
in UR61J cells is induction of ornithine decarboxylase (OD-
Case) gene expression andenzymatic activity (27, 58) . How-
ever, rapid increase in cfos expression, atypical cellular re-
sponse to transforming andother signals, does notoccurafter
expression of oncogenic p21"-r°5 in UR61J cells (58 ; Qiu,
M.-S ., A. F . Pitts, and S. H. Green, unpublished observa-
tions) . Thus, UR61J cells express a specific form of p21-
that canbe inducedbyDEXand that causes distinctive effects
on the cells, effects that are rapidly and easily assessed .
p21- appears as a double band on polyacrylamide gels as
a result of posttranslational processing ; the lower, faster-
running species is theprocessed form (33, 35, 53) . As can be
seen in Fig . 1 A, this lower band represents the predominant
cellular form ofp21- in control, compactin-untreated cells .
Addition of 3 /cg/ml compactin to the culture prevents post-
translational modification of all newly synthesized p21-, in-
cluding the induced oncogenic p21" -ras . This can be seen in
Fig . 1 A as a shift of radiolabeled material from the lower
to upper band of thedoublet . In cells treated with >3 Ecg/ml
compactin the lowerband is no longer prominent and all, or
nearly all, of the newly synthesized p21- is in the upper
band . The lanesfrom cells untreatedwithDEX show endog-
enous p21-, and the lanes from DEX-treated cells show pri-
marily induced p21" --. Both forms of p21- are similarly
affected by compactin treatment .
797Figure 2 . Compactin inhibits association of p21-1 with the mem-
brane . PC12 or UR61J cell proteins were "S-labeled for 24 h as in
Fig . 1, fractionated into nuclear, cytosolic, and particulate fractions
and p21- was immunoprecipitated from particulate and cytosolic
fractions as described under Materials and Methods . The figure
shows p21-5 in the particulate fraction (M), which includes the
membranes, and cytosolic fractions (C) of compactin-treated and
untreated (control) cells : (A) UR61J cells treated for 30 h with com-
pactin at 1 or 3 jig/ml, as indicated, or control compactin-untreated
cells. [35S]Met and 5 ug/ml dexamethasone were present during
the final 24 h of incubation so the immunoprecipitated protein is
primarily oncogenic p21N_°u . (B) PC12 cells treated for 120 h with
compactin at 3 or 6 jig/ml, as indicated, or control untreated cells .
Posttranslational processing of the endogenous p21-, pro-
tein ofPC12 cells is similarly inhibited by compactin (Fig .
1 B) . Control, compactin-untreated PC12 cells exhibit both
fast- and slow-migrating forms ofp21- that give rise to a
double band on PAGE of immunoprecipitates . Compactin
treatment during 35S-labeling causes a shift of radiolabeled
p21-s to the upper band or unprocessed form .
Compactin Ransiently Increases Levels ofp21-
Protein Synthesis in UR61JandPC12 Cells
Fig. 1 shows p21- immunoprecipitated from cellular ho-
mogenates containing approximately equal amounts of 35S-la-
beled protein . In addition to showing a DEX-induced in-
crease in p21- in UR61J cells and a shift of p21-s to the
upper species, Fig . 1 A shows an increase in p21- in com-
pactin-treated UR61J cells . This is true for both the endog-
enous p21- protein in DEX-untreated cells as well as for
the DEX-induced oncogenic p2lN-w . Densitometric scans
of autoradiograms from five separate experiments indicate
that induction of oncogenic p21N-- by DEX causes a 4.5 f
1.1-fold increase in 3IS-labeled p21 "°s protein . Compactin in-
duces a 2.4 f 0.3-fold (n = 3) further increase in 35S-labeled
p21- protein over the DEX-induced increase . In UR61J
cells not treated with DEX, compactin induces a 3.7 f 1.2-
fold (n = 4) increase in "S-labeled p21- protein. Since
p21- has a 24-h half-life in PC12 cells (Qiu,M .-S, and S . H .
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Green, manuscript in preparation), the increase in p21-
protein over the 24-h labeling period must be due mainly to
an increase in p21- synthesis and not to inhibition ofp21-
degradation . Even if degradation of p21- were completely
blocked by the addition of compactin, p21- would exhibit
only a 2-fold increase in compactin-treated cells relative to
control cells, not the 3.7-fold increase that we observe. How-
ever, the possibility does remain that a decrease in p21-
degradation may make a contribution to theprotein increase .
Fig . 1 B shows PC12 cells incubated for 24 or 96 h in the
presence or absence of 3 ug/ml compactin . After a 24-h in-
cubation, the compactin treated cells have an increased level
of p21-s protein synthesis relative to controls . The extent of
this increase is similar to that in non-DEX-treated UR61J
cells . However, this increase in p21- protein synthesis is
transient . After a 96-h incubation, the level ofp21- protein
synthesis is approximately equal in compactin-treated and
untreated PC12 cells .
CompactinBlocksp21ros Membrane Localization
in UR61J andPC12 Cells
In control, compactin-untreated UR61J cells, =80% of the
oncogenic p21 N-ms protein synthesized over a 24-h labeling
period was associated with the cell membrane (Fig . 2 A) .
Oncogenic p21N - ras synthesized in the presence of compactin
was notmembrane associated (Fig . 2 A) : =85% ofoncogenic
p21N-w synthesized in 1 pg/ml compactin was associated
with the cytosolic fraction and >95% of oncogenic p21N-
synthesized in 3 p,g/ml compactin was associated with the
particulate fraction .
Similarly, in control, compactin-untreated PC12 cells,
=70% of the p2l- protein synthesized over a 24-h labeling
period was associated with the cellmembrane (Fig . 2 B) . In
contrast, in compactin-treated cells, >95% of p21-s synthe-
sized in 3 fcg/ml compactin was associated with the cytosolic
fraction and essentially all of the p21- synthesized in 6 wg/
ml compactin was associated with the cytosolic fraction
(Fig . 2B) . In the cells used for Fig . 2B compactin treatment
included a 96-h pretreatment before the 24-h [35Slmethio-
nine labeling in the presence of compactin .
Effects ofcompactin on p21- synthesis, post-translational
processing and membrane localization are entirely reversed
by the addition of 100 AM mevalonate during compactin
treatment (not shown) . Thus, these effects are due to inhibi-
tion of mevalonate biosynthesis by compactin and not to di-
rect effects of compactin on protein isoprenylation .
CompactinBlocks ras-inducedNeuronal
Differentiation in UR61J Cells
Since compactin treatment blocks both p21- posttransla-
tional modification and association with the membrane, it
was expected that such treatment would inhibit neuronal
differentiation induced by oncogenic p21- in PC12 cells
justas such treatment inhibits the activity oftransforming ras
oncoproteins in other systems. Fig . 3 shows the effects of
compactin treatment on ras-induced neuronal differentiation
and UR61J cell morphology. Compactin treatment results in
cell rounding and the formation of small processes or
"spikes ." Both ofthese morphological changes become prom-
inent within 24 h of compactin treatment (Fig . 3 B) . How-
ever, the "spikes" are transient and disappear within 48 h of
798Figure 3 Effects of compactin on UR61J cell morphology. Cells were photographed using phase-contrast microscopy. (A) UR61J cells
in control conditions . (B) Cells treated with 3 l~g/ml compactin for 24 h showing compactin-induced rounding and "spikes," (C) Cells
treated with 5AM dexamethasone for24 h showing initiation of ras-induced neurite outgrowth. (D) Cells treated with 3,ug/ml compactin
for 48 h showing loss ofcompactin-induced "spikes" apparent at 24 hof compactin treatment . (E) Cells treated with 5 AM dexamethasone
for 48 h showing ras-induced neurite outgrowth . (F) Cells treated with 5pM dexamethasone + 3 pg/ml compactin for48 h showing lack
of ras-induced neurite outgrowth . Bar, 100 /Am .
compactin treatment (Fig . 3 D), although the cells remain
rounded .DEXtreatment induces neuriteoutgrowth in UR6IJ
cells which is visible by 24 h (Fig . 3 C) and prominent by
48 hof treatment (Fig . 3 E) as has been previously reported
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(38) . This ras response is entirely abolishedby the addition
of3 pg/ml compactin to theculturemedium during theDEX
treatment(Fig. 3F) . Extendedpretreatmentswith compactin
up to4dbefore addition ofDEX similarly inhibit subsequent
799induction of neurite outgrowth by p21"-"w (data not shown) .
One alternative interpretation is that the compactin treat-
ment does not block ras-induced differentiation but rather
blocks DEX induction of ras transcription from the MMTV
promoter construct . This is unlikely because UR61J cells
treated with compactin and then with DEX do exhibit in-
creased p21 "°á synthesis relative to cells treated with com-
pactin alone (Figs . 1 A and 2 A) . A second alternative in-
terpretation of this experiment is that compactin affects
UR61J cellsmore strongly than it affects PC12 cells because
of some as-yet-unknown metabolic difference between these
clones . To test these two alternatives we transiently ex-
pressed oncogenic p21" -rw in PC12 cells using a constitu-
tive promoter. The construct tll-N-ras(T) (26) contains a
Lys" mutant transforming ras gene, which is expressed
constitutively by an LTR promoter in PC12 cells . When
transfected intoPC12 cells this induces neuronal differentia-
tion at low frequency (26) . We typically see a neuronal ap-
pearance like that in Fig. 3 E in 1-5% of cells transfected
with tl l-N-ras(T) within 48 h after transfection . Under con-
trol conditions we observed between 106 and 5 x 106 neu-
ronal cells among 108 cells transfected with tll-N-ras(T) ;
no neuronal cells were observed among 10 8 similarly trans-
fected PC12 cells shifted to medium containing 3 Fig/ml
compactin . This indicates that compactin directly inhibits
the function of transforming ras genes in PC12 cells .
CompactinBlocks ras-inducedEarly Gene Expression
in UR61J Cells
A possible explanation for the results described above is that
compactin specifically blocks neurite outgrowth but does not
actually block ras activity. To test this possibility, we chose
to assay a rapid response to oncogenic ras expression in
DEX-treated UR6ll cells . Oncogenic ras does not induce
cfos in UR61J cells but does induce a large increase inOD-
Case expression (58) . Also, DEX treatment has only a mini-
mal inhibitory effect on neurite outgrowth or ODCase ex-
pression in PC12 cells (59) . We treated UR61J cells with
DEX for 18 h in the presence and absence of 3 p,g/ml com-
pactin and assayed ODCase expression by Northern blot
(Fig . 4) . DEX treatment in the absence of compactin caused
a large increase in ODCase expression . Compactin treat-
ment alone caused a small but significant increase in OD-
Case expression . However, compactin treatment completely
abolished the large DEX-induced increase in ODCase ex-
pression . Thus compactin apparently blocks even rapid re-
sponses to oncogenic p21 " - r°s .
Compactin Does NotBlock NGF-inducedNeuronal
Di fferentiation in PC12 Cells
PC12 cell p21 °s protein has a half-life of=24 h (Qiu, M.-S. ,
and S . H . Green, manuscript in preparation) . The isoprenyl
moiety on the COOH-terminal cysteine appears to be stable
(33 ; Qiu, M . S ., and S . H . Green, manuscript in prepara-
tion) . Since compactin only blocks isoprenylation of newly
synthesized p21-s and can have no effect on p21-s present
before addition of compactin, PC12 cells were treated for
120 h and 3 /.g/ml compactin beforeassessing their responses
to NGF. With this treatment protocol, >98% of the p21-
present in the cells at the time of NGF addition was synthe-
sized in the presence of 3 jg/ml compactin and was thus nei-
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Figure 4. Effects of compactin on ODCase mRNA expression in
UR61J cells . Total RNA from UR61J cells was probed for ODCase
mRNA as described in Materials and Methods . DEX treatment
was with 5 p,M dexamethasone for 18 h . COM treatment was with
6 wg/ml compactin for 24 h (cells treated withdexamethasone there-
fore received a 6-h pretreatment with compactin) . Averaged den-
sitometer scans of three autoradiograms indicates that DEX treat-
ment alone caused a sevenfold increase in ODCase expression ;
COM, a threefold increase ; DEX + COM, a threefold increase .
ther isoprenylated nor membrane-associated . An extended
pretreatment was not necessary in experiments performed
with UR6ll cells because synthesis of oncogenic p21- , was
not initiated until after compactin had been added .
Treatment ofPC12 cells with NGF leads, within 24 h, to
flattening and extension of short processes (28) . Extension
of neurites is apparent within 48 h and prominent by 72 h
ofNGF treatment (Fig . 5 B) . Within 24 h, 3 /Ag/ml compac-
tin induced cell rounding and transient "spikes" inPC12 cells
similar to those induced in UR61J cells (Fig . 5 C) . Possibly
associated with the morphological change was a reduction in
adhesion of PC12 cells to the substrate observed as an in-
crease in the number of cells in suspension in the culture .
These contrast with the well-described flattening, substrate
adhesion, and long, permanent processes induced by NGF.
As with UR61J cells, the spikes disappear after 24-48 h of
treatment . After 120 h ofcompactin treatment, the spikes are
gone and the toxicity of compactin becomes evident (Fig . 5
D) : 21% of the original population of PC12 cells is dead .
Treatment with compactin for an additional 72 h results in
death of >95% ofthe original population (Fig . 5 E) . In con-
trast, if NGF is added with compactin for this 72-h period
then continued cell death is greatly reduced (Fig . 5 F) . Fig .
5 F also demonstrates that NGF promotion of cell survival
was not compromised by compactin . In the absence of se-
rum, NGF is sufficient to maintain PC12 cell survival (23) .
PC12 cells that carry mutations which eliminate their ability
to respond to NGF do not survive in NGF-supplemented
serum-free medium (21) . However, compactin-pretreated
PC12 cells maintained for 72 h in NGF-supplemented serum-
free medium survive, thus demonstrating that the neuro-
trophic effect of NGF is not blocked by compactin . These
NGF-treated PC12 cells, which represent 79% of the origi-
nal population, were pretreated with 3 pg/ml compactin for
800FigureS . Effects of compactin on morphology of NGF-treated and -untreated PC12 cells . Cells were photographed using phase-contrast
microscopy. (A) PC12 cells in control conditions : no NGF, no compactin . (B) Cells treated with 50 ng/ml NGF for72 hshowing initiation
of NGF-induced neurite outgrowth . (C) Cells treated with 3,ug/ml compactin for 24 h showing compactin-induced rounding and "spikes."
(D) Cells treated with 3 j,g/ml compactin for 120 h showing progress of compactin-induced cell death . (E) Cells treated with 3 jug/ml
compactin for 192 h showing compactin-induced cell death . (F) Cells treated with 3 gg/ml compactin for 120 h, then 3 wg/ml compactin
plus 50 ng/ml NGF for 72 h in serum-free medium showing (1) NGF-induced neurite outgrowth typical of PC12 cells treated with NGF
for 72 h, and (2) prevention of the compactin-induced cell death evident after 192 h of compactin treatment in the absence ofNGF . All
pictures except D are at the same magnification ; bar, 100 /Am .
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treated PC12 cells . Total RNA from PCl cells was probed for
ODCase mRNA as described in Materials and Methods . NGF
treatmentwas 50 ng/ml NGF for 3 h . COM treatment was 3 1g/
ml compactin for 120 h .
5 d, a condition in which <2% of the cellular p21
ros is iso-
prenylated and membrane-associated . Thus p21ros isopreny-
lation and membrane-association is not required for NGF
maintenance of cell survival .
p21- isoprenylation and membrane-association is also
not required forNGF induction of neurite outgrowth: PC12
cells treatedwithNGF plus 3 pg/mlcompactin for72 h, after
pretreatment with 3 pg/ml compactin for 120 h (Fig . 5 F),
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extend neurites similar in length and quality to those ex-
tended in 72 h the absence of compactin (Fig. 5 B) . Under
control conditions, NGF-induced neurites extend 45 f 24
Am (n = 60) in 72 h; after compactin treatments that elimi-
nate >98% of membrane-associated p21-, NGF-induced
neurites extend 47 f 26 p,m (n = 70) in 72 h. The number
of cells bearing neurites of length >2 cell diameters at 72 h
is reduced from 69% in control conditions to 46% in com-
pactin, possibly due to loss of substrate adhesion .
Compactin DoesNotBlock NGF-induced EarlyGene
Expression inPC12 Cells
NGF, like oncogenic p21-s, induces ODCase expression in
PC12 cells . However, inductionby NGF, unlike that by onco-
genic p21-, is not inhibited by compactin treatment . PC12
cells exposed to 3 P.g/ml compactin for 120 h to eliminate
membrane-associated p21- were treated with NGF for 3 h
and total cellular RNA wasprobed for ODCase on a North-
ern blot . Expression ofODCasemRNA was equal in control
and compactin-treated cells (Fig . 6) . Fig . 6 also shows that
theinductionofODCaseby compactin, apparent aftera24-h
treatment with the drug (Fig . 4), is no longer apparent after
a 120-h treatment with compactin .
Compactin DoesNotBlock NGF- or EGF-stimulated
Phosphorylation of Tyrosine Hydroxylase
NGF and EGF (epidermal growth factor) stimulate rapid
Figure 7 . Phosphoproteins in PC12 cells treated with NGF, EGF, or compactin . Phosphoproteins were labeled with ["P]orthophosphate
under various conditions as described in Materials and Methods . Positions of molecular weight standards are indicated adjacent to each
autoradiogram . (A) Compactin-treated cells were so treated for 120 h with 6 Wg/ml compactin . Control cells (C) were not treated with
growth factors ; the other lanes show phosphoproteins from NGF-treated (N) or EGF-treated cells (E) . The position of the 60-kD phos-
phoprotein is indicated by the arrow. Averaged densitometer scans of three autoradiograms indicates that COM treatment alone caused
a 4-fold increase in phosphorylation of the60-kD protein ; NGFalone, a9.6-fold increase ; EGFa 5.7-fold increase . In the compactin-treated
cells, NGFcaused a4.2-fold increase in phosphorylation ofthe60-kD protein and EGF caused a3.0-fold increase . (B) Compactin treatment
was with 10 tg/ml compactin for the times indicated . The position of the60-kD phosphoprotein is indicatedby an arrow ; that of a 24-kD
compactin-induced phosphoprotein by an arrowhead . Increase in density of the 24-kD protein was 2.4-fold at 24 h and 5.9-fold at 48 h
with no significant change due to NGF treatment .phosphorylation of a number of PC12 cell proteins, notably
a 60-kD species thought to be tyrosine hydroxylase (TH)
(31, 46, 54) . The increase in phosphate content of this spe-
cies as a result of 1 h of NGF or EGF treatment is shown in
Fig. 7 A . Prior exposure to 6 pg/ml compactin for 120 h to
eliminate membrane-associated p2 1-s inhibits neither NGF-
nor EGF-stimulated phosphorylation of TH (Fig. 7 A) . This
treatment with compactin does itself reproducibly stimulate
phosphorylation of TH, as can be seen by comparing the in-
tensity of the 60-kD species in the lanes from compactin-
treated and compactin-untreated cells. Fig. 7 B shows that
the compactin induced stimulation of TH phosphorylation is
detectable within 24 h ofaddition of compactin and is promi-
nent within 48 h . Compactin treatment of PC12 cells also in-
duces the appearance of a novel 24-kD protein, apparent
within 24 h and prominent by 48 h of treatment (Fig. 7 B).
Fig. 7 A shows that this 24-kD phosphoprotein is transient,
not visible after 120 h of compactin treatment.
Compactin Blocks NGF- and EGF-induced Rapid
Changes in Surface Morphology
NGF and EGF treatment both rapidly induce an increase
in PC12 cell surface motility, although by somewhat different
mechanisms (15, 54) . This motility is most easily observable
as the appearance of large lamellipodiae or "ruffles" after
NGF or EGF treatment (Fig. 8, B and F). PC12 cells treated
with compactin (1 1~g/ml for 24 h) completely lack this re-
sponse to growth factor stimulation (Fig. 8, D and H) . This
inhibition of membrane motility is general, affecting both
EGF- and NGF-induced ruffling, however, this does not im-
ply that p21ros acts as a signal transducer for this response
for either growth factor. Inhibition of ruffling occurs after a
regime of compactin treatment (1 1.g/ml for 24 h) which
results in only a partial blockade of isoprenylation of newly
synthesized p21- and does not allow sufficient time for
replacement of previously synthesized p21-s. These figures
also show compactin-induced cell rounding and loss of
cell-cell adhesion consistent with that shown above in cells
observed by phase contrast microscopy.
Effects ofCompactin on PC12 Cells
While compactin and lovastatin do not significantly reduce
the NGF responses we investigated in PC12 cells, these in-
hibitors of mevalonate biosynthesis are not without effects
on these cells. For example, we have observed compactin in-
hibition of p21-s processing, p21- membrane localization
and function, inhibition of growth factor-induced rapid
changes in surface morphology, induction of morphological
changes such as rounding and "spiking," a small transient in-
crease in ODCase expression, an increase in tyrosine hydrox-
ylase phosphorylation, and a transient increase in expression
of p2l- and a 24-kD phosphoprotein. These compactin-in-
duced changes do not occur if the cells are compactin-treated
in the presence of 100 j,M mevalonate (not shown). Thus,
these changes are a direct result of compactin inhibition of
mevalonate biosynthesis. The major mevalonate-derived
product in cells is cholesterol; however, it is unlikely that the
effects observed in PC12 and UR61J cells as a result of com-
pactin treatment are due to cholesterol deprivation. The cul-
ture medium contains =130 Ag/ml cholesterol derived from
the added calfand horse sera (information supplied by Hazle-
ton Biologics, Inc.) . Tracer [3H]cholesterol was added to
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the culture medium and uptake was assayed as described in
Materials and Methods. Compactin-treated PC12 cellstook
up 15% of the total available cholesterol pool over a 3-d in-
cubation period. This indicates that the supply of cholesterol
to the cells is not limiting and PC12 cell responses to com-
pactin are not likely to be a result of cholesterol starvation .
Nevertheless, compactin responses are not necessarily a re-
sult of inhibition of protein isoprenylation. Mevalonate is
used in the biosynthesis of many cellular products and the
relevance of all of these has not yet been investigated.
Discussion
Isoprenylation ofp21"- Proteins Is Requiredfor
their Promotion of Neuronal Di fferentiation
Previous studies, summarized above, have shown that
isoprenylation of mammalian p21-, is required for its fur-
ther posttranslational processing and association with the
cell membrane (33, 35, 45, 53). Isoprenylation is likewise
necessary for transforming activity of oncogenic p21-, in
mammalian cells (35). Inhibition of isoprenylation results in
the lack of all subsequent posttranslational processing of ras
proteins: carboxyl methylation, removal of the AAX
COOH-terminal tripeptide, palmitoylation and localization
to the membrane. In view of the observation that mutant on-
cogenic p21H-- and p21"-'°s proteins that are isoprenylated,
but not palmitoylated, exhibit reduced association with the
membrane in parallel with reduced transforming activity
(33), it is most likely that membrane localization is the pro-
cess critical for function of ras proteins.
We show here that in PC12 cells, as well, isoprenylation
of p2l- is required for its further posttranslational process-
ing and association with the cell membrane. Expression of
oncogenic p21- in PC12 cells results in neuronal differenti-
ation not transformation (5, 26, 46). These observations allow
us to use compactin treatment of PC12 cells to determine
whether p21- isoprenylation and membrane association is
required for neuronal differentiation as it is for transforma-
tion. We find that this is indeed the case, inhibition of iso-
prenylation and membrane association abolishes PC12 re-
sponses to expression of oncogenic p2IN-"°s. This implies
that these two different classes of responses, mitogenesis and
differentiation, are both mediated by a mechanism requiring
p21- isoprenylation.
The Role ofp21- in NGFSignal 7ïnansduction
Evidence for Involvement of p21- in NGF Signal TiRans-
duction. Responses to oncogenic p21-, transformation,
and differentiation, require isoprenylation. Is this also the
case for functions of normal p21- in signal transduction in
mammalian cells? To determine this we chose to examine the
effect of compactin treatment on NGF responses in PC12
cells because three lines of evidence suggest that p21- has
a role in NGF signal transduction. Although each observa-
tion alone has alternative interpretations, as detailed below,
the aggregate, whilenot conclusive, appears to strongly sup-
port this idea .
(a) Expression of mutant transforming ras gene products
in PC12 cells induces neuronal differentiation similar to
that induced by NGF (5, 61, 49) . However, it is possible that
ras-induced neuronal differentiation results from the activa-
803tion, by oncogenic p21-, of an intracellular signal pathway
different from the one activated by NGF In support of this
second possibility are observations of differences between
NGF-induced responses and ras-induced responses in PC12
cells. For instance, NGF, but not transforming ras, induces
expression of cfos in PC12 cells(27; Qiu, M.-S., A. F Pitts,
and S.H. Green, unpublished observations). Also, down-
regulation of kinase C has a stimulatory effect on ras-
induced ODCase expression and neurite growth (50) but this
same treatment partially inhibits NGF-induced cfos expres-
sion (55) and ODCase expression (Mesner, P., and S.H.
Green, unpublished observations) . Thus, the observation
that transforming ras mimics NGF responses is, by itself, not
evidence that it functions as a signal transducer for the NGF
receptor. Furthermore, treatment with EGF activates p21 "°á
in PC12 cells to the same extent as does NGF (Qiu, M.-S.,
and S. H. Green, manuscript in preparation) yet does not in-
duce neuronal differentiation. Thus, expression ofoncogenic
p21N-- in PC12 cells is not equivalent to growth factor-me-
diated activation of the cells' endogenous p21-s and induc-
tion of neuronal differentiation by oncogenic p21N-- does
not imply that normal p21- is involved in NGF signal trans-
duction.
(b) Expression of oncogenic p21N-- s in UR61J cells in-
hibits subsequent cfos induction by NGF, but not by epider-
mal growth factor, phorbol-12-myristate-13-acetate (PMA),
forskolin, or depolarization with K+ (58). While this result
implies an interaction between NGF and oncogenic p21-s
intracellular signaling mechanisms, it does not specify the
type of interaction and, in particular, does not imply that
p21-5 is required for NGF signal transduction.
(c) Blockade of p21- activity by microinjection of Y13-
259 antibody (30) or expression of Ha-ras Asn-17, a domi-
nant inhibitory mutant ras gene, (57) inhibits responses to
NGF However, this inhibition may result from a general
effect on cell physiology rather than a specific effect on signal
transduction. Another difficulty is that in the study of Sze-
berdnyi et al., not all cell linestransfected with the inhibitory
mutant ras gene were NGF nonresponsive ; some lines ex-
pressing Ha-ras Asn-17 possessed NGF responses, although
most did not (57). Possibly, if both ras-dependent and ras-
independent NGF signal transduction pathways existin PC12
cells, a subset of cells that lose the ras-dependent pathway
as a result of a spontaneous mutation lose all ability to re-
spond to NGF if the ras-dependent pathway is subsequently
eliminated. Cells retaining the ras-independent pathway
would respond to NGF even if expressing Ha-ras Asn-17,
p21- Membrane Association Is Not Necessaryfor NGF
Signal Transduction. This study further defines the role of
p21-s in NGF signal transduction. We examined a variety
of responses to NGF : an early transcription-independent re-
sponse (phosphorylation of tyrosine hydroxylase) ; an early
transcription-dependent response (induction of ODCase);
and late responses, neurite outgrowth and cell survival . Our
results indicate that association of p21- with the membrane
is not necessary for responses to NGF. Since currently avail-
able evidence, supported by the datapresentedhere, indicates
that p2l- must be membrane-associated to be functional,
we conclude that it is unlikely that NGF signal transduction
is mediated exclusively by a p21-5-dependent mechanism.
Rather, we favor a NGF signal transduction mechanism that
involves multiple parallel signal pathways with p21rot in-
volved in some but not all of them . However, we have con-
sidered four other possible explanations of our data; for the
reasons given, we do not believe that these can account for
all of our results.
(a) UR61J cells and PC12 cells may have metabolic differ-
ences that cause the former but not the latter to be sensitive
to compactin. This is unlikely because (a) compactin blocks
p2l- posttranslational processing and membrane associa-
tion in both PC12 and UR61J cells, and (b) neurite outgrowth
induced by expression of oncogenic p21- in PC12 cells is
blocked by compactin just as it is in UR61J cells.
(b) Another explanation for our results might be that long-
term treatment of PC12 cell cultures with compactin results
in a selection for a subpopulation of compactin-resistant
cells which can function normally with reduced mevalonate
levels. This possibility is ruled out by the observations that
(a) a 5-d treatment with 3 pg/ml compactin kills only 21%
of the cells. Therefore, if there existed a compactin-resistant
subpopulation it would encompass =80 % ofthe population.
If this were so then we would have been unable to observe
effects of compactin on p21- processing. (b) All compactin-
treated PC12 cells fail to exhibit growth factor-induced rapid
changes in surface morphology, indicating that there are no
cellsresistant to compactin by this criterion. (c) Compactin-
treated UR61J cells fail to respond to oncogenic p21-s even
after 4-5-d compactin pretreatments comparable to those
used for studies of PC12 NGF responses (Pitts, A . F., and
S. H . Green, unpublished observations) in spite of a com-
parable degree of cell death. Thus, there is no selection for
compactin resistant UR61J cells. (d) Most importantly,
p21- is cytosolic in the cells treated with 3 Ag/ml compac-
tin in the long-term (Fig. 2 b). Thus, isoprenylation of
p21- in both PC12 and UR6IJ cells is sensitive to long-term
compactin treatments and long-term treatment with this drug
is an effective means of blocking membrane-p21- associ-
ation.
(c) Compactin treatment results in a nearly complete pre-
vention of association of p21- with the membrane. Possi-
bility, the remaining component is sufficientto fully maintain
NGF signal transduction. However, this possibility is un-
likely because these same compactin treatments completely
block actions of oncogenic p21N-"° S.
(d) Our results show that NGF signal transduction is not
inhibited by treatments that block membrane association of
Figure 8. Inhibition by compactin of growth factor-induced membrane movements in PC12 cells. PC12 cells, cultured in 35-mm dishes,
were viewed using Hoffman optics and continuously photographed with a video camera. Cultures treated with compactin (C, D, G, and
H) received 1 ug/ml compactin for 24 h. Video frames transferred to film and reproduced here depict PC12 cells 1 m or 9 m afteraddition
ofgrowth factor (50 ng/ml NGF or 3 ng/ml EGF). After 1 m ofgrowth factor treatment, PC12 cells have not yet begun to exhibit lamellipo-
diae visible by Hoffman optics and thus demonstrate the quiescent state, while at 9 m such membrane movements have reached a plateau
of intensity. Representative lamellipodiae are indicated by small arrows. (A) 1 m NGF, (B) 9 m NGF, (C) 1 m NGF, (D) 9 m NGF, (E)
1 m EGF (F) 9 m EGF, (G) 1 m EGF (H) 9 m EGF.
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tion is mediated by a cytoplasmic effector that does not re-
quire p21- to be membrane associated . However, this
would imply that the mechanisms of action of oncogenic and
normal p21- are different in that the former, but not the
latter, requires association with themembrane to achieve its
effects ; compactin clearly blocks oncogenic p21 .°á actions
in PC12 cells . Although it has been suggested (10) that nor-
mal and oncogenic p21- may interact with different effec-
tors, there is no evidence that these proteins differ in require-
ment for membrane association for their effects (47, 62),
therefore such an observation would be remarkable . Further
study is required to characterize p21- effector proteins and
determine whether normal and oncogenic ras gene products
differ in their interactions with these proteins . If it is the case
that normal and oncogenic p21-s achieve their effects via
different mechanisms then the ability of oncogenic p21-5 to
mimic the action ofNGF can't be interpreted as supporting
the idea that p21-, is involved in NGF signal transduction .
Ras-dependent and ras-independent NGF Signal Trans-
duction . The data presented here indicate that ras is not
necessary for NGF signal transduction although p21- may
be involved in NGF signal transduction, as suggested by the
studies summarized above . We hypothesize that p21"°s func-
tion is not necessary for NGF signal transduction because
the NGF receptor is associated with multiple intracellular
signaling pathways including ras-independent pathways and
possibly one or more ras-dependent pathways . Elimination
of ras function by compactin treatment would then result in
only apartial loss oftheNGF signal transduction mechanism
with the remaining ones able to induce the NGF responses
observed in this study .
The existence of multiple signaling pathways initiated by
receptor tyrosine kinases has been well-documented (10) .
Activation of p21- is only one of the pathways involved .
NGF also induces tyrosine phosphorylation ofmultiple sub-
strates (38, 39) and therefore is also likely to activate several
intracellular signaling pathways . In favor of the idea that
parallel pathways exist in NGF signal transduction is the
observation that inhibition of some, but not all, protein-
serine/threonine kinases by adenosine analogues abolishes
some, but not all, responses to NGF (25, 61), whereas more
general inhibition of kinases by K-252a eliminates all PC12
cell responses to NGF (34, 39, 50) . Other studies have pro-
vided evidence for convergence of separate protein-serine/
threonine kinase pathways in NGF-induced tyrosine hydrox-
ylase phosphorylation in PC12 cells (16, 46) . Furthermore,
we have observed that downregulation of protein kinaseC re-
sults in a partial inhibition of ODCase induction, and Sig-
mund et al . (55) have shown a similar effect of kinase C
downregulation on induction of cfos . This implies that tran-
scriptional activation of these genes involves multiple signal
transduction pathways with protein kinase C being one of
them . Then, p21-, may function in one or more parallel in-
tracellular signaling pathways, exclusive ofprotein kinase C,
but in the absence of p2l o, function, the remaining path-
ways are able to induce the NGF responses observed in this
study.
Compactin-induced Responses in PC12 Cells
We have also shown a compactin-induced increase in p21-s
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protein synthesis in PC12 cells treated for 24 h with compac-
tin . Two additional observations indicate that this effect is
specific for p21- , (Qiu, M .-S., and S.H . Green, manuscript
in preparation) : the overall level of protein synthesis, as de-
termined by ['SS]methionine uptake into TCA-precipitable
material, is unaffected by a 24-h treatment with compactin,
and the synthesis rate of a nonisoprenylated protein, ß-tubu-
lin, is not affected by compactin . The observed increase in
p21-, synthesis is observed not only for the endogenous
cellular ras gene product but also for the product of a ras
gene introduced by transfection . Since the introduced ras
gene has a viral glucocorticoid-responsive promoter replac-
ing the cellular 5'-flanking genomic sequence, the effect of
compactin on ras expression is not likely to be purely a result
of transcriptional regulation . We are currently investigating
the mechanism by which compactin affects ras mRNA and
protein levels (Qiu, M.S ., and S.H . Green, manuscript in
preparation) .
A rapid change in cell surface morphology is virtually the
earliest cellular response to growth factors ; with scanning
electron microscopy the motility is observable within 30 s
(14, 15) . Compactinblocks rapidchanges in cell surface mor-
phology induced by NGF orEGF without effect on other re-
sponses to these factors . This indicates that although the sur-
face motility precedes other responses it is not a prerequisite
for them .
We have demonstrated that among the effects ofcompactin
on cell metabolism are some which resemble, or interact
with, those of growth factors . These include NGF-inhibited
cell death ; cell surface morphological changes, particularly
the induction of short processes or "spikes," and inhibition
of growth factor-induced membrane motility ; induction of a
novel 24-kD phosphoprotein . Membrane morphological
changes and inhibition of proliferation have been observed
previously (40, 41, 42, 44) . Since these effects are all re-
versed by addition ofmevalonate to the culture medium, they
are apparently due directly to compactin inhibition of meva-
lonate biosynthesis. HMG-CoA reductase, the enzyme in-
hibited by compactin, has a structure like that ofG protein-
coupled receptors and may be involved in the regulation of
cellular metabolism (20) . Possibility, regulation of cellular
proliferation and physiology by metabolic demand for me-
valonate involves some of the same intracellular signaling
mechanisms as do growth factor receptors in their regulation
of cell division. ThatNGF protects PC12 cells from compac-
tin-induced cell death implies that the mechanism by which
compactin kills PC12 cells may be more closely related to
an interaction with growth factor signaling pathways, and de-
velopmental programmed cell death, than to simple cyto-
toxicity .
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